Home

commencer Condenser violoniste novartis zolgensma press release miroir de porte musicien soudainement

Novartis releases long-term Zolgensma data
Novartis releases long-term Zolgensma data

AMM européenne pour Scemblix® (asciminib) de Novartis
AMM européenne pour Scemblix® (asciminib) de Novartis

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge

Novartis allies with Voyager to develop gene therapies in $1.3bn deal
Novartis allies with Voyager to develop gene therapies in $1.3bn deal

Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters
Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters

R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence

Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR
Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR

Test Achats porte plainte contre un médicament à 2 millions d'euros
Test Achats porte plainte contre un médicament à 2 millions d'euros

Path clears for Novartis's Zolgensma after FDA lifts longstanding hold
Path clears for Novartis's Zolgensma after FDA lifts longstanding hold

Japan's health insurance to cover ¥167 million gene therapy drug - The Japan Times
Japan's health insurance to cover ¥167 million gene therapy drug - The Japan Times

FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace
FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace

Novartis faces serious delays in registration of Zolgensma in Russia
Novartis faces serious delays in registration of Zolgensma in Russia

Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor

Novartis' 'full-court press' key to ensuring rapid Zolgensma access
Novartis' 'full-court press' key to ensuring rapid Zolgensma access

Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Novartis Boosts Zolgensma Production Capacity After FDA Clearance

Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma
Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma

Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility

Four Takeaways from the Zolgensma Pricing Storm
Four Takeaways from the Zolgensma Pricing Storm

Novartis releases long-term data for SMA gene therapy
Novartis releases long-term data for SMA gene therapy

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Zolgensma gene therapy for sma patients: long-term data
Zolgensma gene therapy for sma patients: long-term data

Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve | Fierce Pharma
Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve | Fierce Pharma

Novartis used faulty data for world's most expensive drug Zolgensma
Novartis used faulty data for world's most expensive drug Zolgensma

Novartis Media Release guide - August 2019
Novartis Media Release guide - August 2019

ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients
ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients